BRY 812
Alternative Names: BRY-812Latest Information Update: 10 Sep 2025
At a glance
- Originator BioRay Pharmaceutical
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Apoprotein stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 May 2025 Efficacy, adverse events and pharmacokinetic data from a phase I trial in Solid tumour presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 30 May 2025 BioRay Pharmaceuticals plans phase Ib trial in Solid tumours
- 14 Aug 2023 Phase-I clinical trials in Solid tumours in China (IV) (BioRay Pharamceuticals pipeline, August 2023)